In the War Against Solid Tumors Arsenic Trioxide Need Partners
- 298 Downloads
In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.
KeywordsThymidylate synthase miRNA Hedgehog signaling Combination therapy ATO Solid tumor malignancies Arsenic-containing compounds
This work was supported by NCI 1R21CA117116-01A2, Sheibar Foundation, and McDonald Research foundation grants to BA. Additional support was provided by the American Cancer Society Institutional Research Grant (IRG no. 98-277-07), Interdisciplinary Research Development Initiative (IRDI no. 102504) award, and University of Miami Clinical and Translational Science Institute (CTSI) Pilot Research Grant (CTSI-2013-P03) to PRS. The Pilot and Collaborative Translational and Clinical Studies component is supported by Grant No. 1UL1TR000460, the University of Miami CTSI, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. In our effort to keep this article concise and focused, we regret not to have included all citations.
Conflict of interest
We declare no competing interests.
- 5.Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–61.PubMedGoogle Scholar
- 22.Subbarayan PR, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. Anticancer Res. 2010;30:1149–56.PubMedGoogle Scholar
- 31.Robbins DJ, Fei DL, Riobo NA. The Hedgehog signal transduction network. Sci Signal 2012; 5:re6.Google Scholar
- 33.Shi T, Mazumdar T, Devecchio J, Duan ZH, Agyeman A, Aziz M et al. cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PLoS One 2010; 5.Google Scholar
- 43.Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, Kang CM, et al. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res. 2004;64:8960–7.PubMedCrossRefGoogle Scholar